The Okairos technology has already been tested in clinical
studies involving more than 700 subjects, including mid-stage
Phase II programmes in hepatitis C and malaria.
* Swiss-based Okairos specialises in potent T-cell vaccines
* Technology uses deactivated chimpanzee viruses as vectors
* Programmes include Phase II hepatitis C, malaria vaccines
* Privately owned Okairos spun out from Merck in 2007
LONDON, May 29 (Reuters) – GlaxoSmithKline is
betting on a new vaccine technology based on chimpanzee viruses
by acquiring Swiss-based Okairos for 250 million euros ($321
million) – the latest bolt-on biotech buy by a big drugmaker.
Britain’s largest pharmaceuticals group said on Wednesday
that the privately owned company’s know-how was expected to play
an important role in GSK’s development of vaccines to both
prevent and treat diseases.